Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, Italy, comments on the efficacy of fixed-duration treatment in chronic lymphocytic leukemia (CLL). Numerous trials including the Phase III GAIA/CLL13 trial (NCT02950051), which assessed standard chemoimmunotherapy versus a combination of ibrutinib, obinutuzumab, rituximab, and venetoclax, and the Phase III CLL14 trial (NCT02242942), which investigated venetoclax and obinutuzumab, have shown fixed-duration treatment to result in undetectable MRD (uMRD) in a majority of patients. Data from the Phase II CAPTIVATE trial (NCT02910583) of ibrutinib and venetoclax additionally demonstrated that a long-term durable response is achievable even if patients do not achieve uMRD. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

свернуть